Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SER-A-GEN vs ALDORIL D50
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SER-A-GEN is a serotonin receptor agonist that selectively activates 5-HT1A and 5-HT2A receptors, modulating neurotransmitter release in the central nervous system.
Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.
Major Depressive Disorder,Generalized Anxiety Disorder,Obsessive-Compulsive Disorder (off-label)
Hypertension (first-line or second-line therapy),Hypertensive urgency (off-label)
500 mg orally once daily.
1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.
8 ± 2 hours; prolonged to 20-30 hours in severe renal impairment (Cr Cl <30 m L/min).
3–6 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for sustained blood pressure control; prolonged in renal impairment.
Hepatic via CYP3A4 and CYP2D6 isoenzymes; undergoes glucuronidation to inactive metabolites.
Methyldopa is extensively metabolized in the liver via conjugation and O-methylation, with involvement of catechol-O-methyltransferase (COMT). Hydrochlorothiazide is not extensively metabolized; it is eliminated largely unchanged by the kidneys.
Primarily renal: 70% unchanged drug; 20% as glucuronide conjugate; <5% fecal.
Renal: 50% as unchanged drug and 20% as metabolites; biliary/fecal: ~25% (as metabolites); total renal clearance accounts for ~70% of elimination.
92% primarily to albumin; also binds α1-acid glycoprotein.
~20% bound to albumin; minimal binding to other plasma proteins.
0.45 ± 0.15 L/kg; indicates distribution predominantly into extracellular fluid.
0.2–0.3 L/kg (moderately low Vd, indicating limited extravascular distribution and predominantly plasma water distribution).
Oral: 65-75% with first-pass metabolism; intramuscular: 100%.
Oral: 30–40% (due to extensive first-pass metabolism); IV: 100%.
GFR 30-50 m L/min: 250 mg once daily; GFR <30 m L/min: 250 mg every other day; dialysis: 250 mg three times weekly after dialysis.
Contraindicated if GFR < 30 m L/min; for GFR 30-50 m L/min: reduce dose and monitor electrolytes.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: use not recommended.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and monitor; Class C: contraindicated.
Weight ≥10 kg: 10 mg/kg orally once daily; maximum 500 mg daily.
Not recommended; inadequate safety data.
No specific dose adjustment; monitor renal function and reduce dose per renal adjustment if Cr Cl <50 m L/min.
Start with 1 tablet (hydrochlorothiazide 12.5 mg + methyldopa 125 mg) once daily; increase slowly; monitor for hypotension and electrolyte imbalance.
None
None
Serotonin syndrome risk when co-administered with other serotonergic drugs; QT prolongation at high doses; hepatic impairment requires dose adjustment; discontinuation syndrome upon abrupt cessation.
Sedation and drowsiness common; avoid driving or hazardous activities. Risk of Coombs-positive hemolytic anemia with methyldopa (discontinue if anemia develops). Hepatotoxicity and liver function abnormalities (discontinue if jaundice occurs). Orthostatic hypotension; caution in volume-depleted patients. Electrolyte imbalances (particularly hypokalemia, hyponatremia) with hydrochlorothiazide; monitor serum electrolytes. Sulfonamide cross-sensitivity possible. Exacerbation of systemic lupus erythematosus. Avoid abrupt withdrawal of methyldopa (may cause rebound hypertension).
Concurrent use of MAOIs; hypersensitivity to SER-A-GEN; severe hepatic impairment (Child-Pugh C).
Active hepatic disease (cirrhosis, hepatitis) associated with methyldopa therapy; previous methyldopa-induced liver disorders. Anuria or hypersensitivity to thiazide diuretics or sulfonamide-derived drugs. Concomitant use with MAO inhibitors. Severe renal impairment (creatinine clearance <30 m L/min) or electrolyte depletion due to hydrochlorothiazide. Concurrent lithium therapy (risk of lithium toxicity).
Avoid grapefruit and grapefruit juice as they may increase serum levels and risk of toxicity. No other significant food interactions known; take with or without food.
Avoid potassium supplements or salt substitutes containing potassium without consulting doctor. Limit alcohol intake. Avoid excessive grapefruit juice. Maintain adequate potassium intake through diet to prevent hypokalemia.
First trimester: Associated with neural tube defects (NTDs), cardiovascular malformations, and oral clefts. Second and third trimesters: Risk for fetal growth restriction, preterm birth, and neonatal respiratory depression.
Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester may cause fetal/neonatal effects including electrolyte disturbances, jaundice, thrombocytopenia, and possible fetal growth restriction. Methyldopa has not shown teratogenicity. Aldoril D50 (M 500mg/HCTZ 50mg) is not recommended during pregnancy, especially after first trimester.
Excreted into breast milk in low concentrations; M/P ratio 0.25. Potential for infant sedation and poor feeding. Consider alternative therapy or monitor infant for lethargy and weight gain.
Both methyldopa and HCTZ are excreted in breast milk. Methyldopa M/P ratio approximately 1.0; HCTZ M/P ratio variable, small amounts. Use during breastfeeding may suppress lactation due to HCTZ diuretic effect. Monitor infant for signs of hypotension, electrolyte imbalance. Caution recommended; use only if clearly needed.
Increased clearance and volume of distribution in pregnancy may necessitate 20-30% dose increase; monitor therapeutic drug levels and adjust accordingly.
Pregnancy-induced increase in plasma volume may reduce effectiveness of HCTZ, requiring dose adjustment. Methyldopa pharmacokinetics not significantly altered; however, increased clearance in pregnancy may require higher doses. In preeclampsia, dose adjustments may be needed. Avoid HCTZ in pregnancy if possible.
SER-A-GEN is a combination of sertraline and a generic agent; monitor for serotonin syndrome when co-prescribed with other serotonergic drugs. Use with caution in patients with hepatic impairment; start at lower doses. Abrupt discontinuation may cause withdrawal symptoms; taper gradually.
ALDORIL D50 combines methyldopa and hydrochlorothiazide. Monitor for orthostatic hypotension, especially in volume-depleted patients. May cause positive Coombs test, hemolytic anemia, and lupus-like syndrome. Avoid in pheochromocytoma. Use caution in hepatic disease.
Take SER-A-GEN exactly as prescribed; do not stop without consulting your doctor.,It may take several weeks to feel the full benefit; continue taking it even if you feel well.,Avoid alcohol while taking this medication.,Report any symptoms of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate, fever, muscle stiffness) immediately.,Do not take with other antidepressants or migraine medications without medical advice.
Take exactly as prescribed; do not skip doses or double up.,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Report unexplained fever, jaundice, or dark urine immediately.,Avoid sudden discontinuation; may cause rapid increase in blood pressure.,Stay hydrated but do not overhydrate; monitor for signs of electrolyte imbalance.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SER-A-GEN vs ALDORIL D50, answered by our medical review team.
SER-A-GEN is a Antihypertensive Combination that works by SER-A-GEN is a serotonin receptor agonist that selectively activates 5-HT1A and 5-HT2A receptors, modulating neurotransmitter release in the central nervous system.. ALDORIL D50 is a Antihypertensive Combination that works by Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SER-A-GEN and ALDORIL D50 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SER-A-GEN is: 500 mg orally once daily.. The standard adult dose of ALDORIL D50 is: 1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SER-A-GEN and ALDORIL D50 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SER-A-GEN is classified as Category C. First trimester: Associated with neural tube defects (NTDs), cardiovascular malformations, and oral clefts. Second and third trimesters: Risk for fetal growth restriction, preterm . ALDORIL D50 is classified as Category C. Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.